

AWARD NUMBER: **W81XWH-16-1-0472**

TITLE: **Targeting BRCAness in Gastric Cancer**

PRINCIPAL INVESTIGATOR: **Lawrence Fong, MD**

CONTRACTING ORGANIZATION: **The Regents of the University of California, San Francisco**

REPORT DATE: **Oct 2019**

TYPE OF REPORT: **ANNUAL**

PREPARED FOR: **U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**

DISTRIBUTION STATEMENT: **Approved for Public Release;  
Distribution Unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
*OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> October 2019			<b>2. REPORT TYPE</b> ANNUAL		<b>3. DATES COVERED</b> 15 Sep 2018-14 Sep 2019	
<b>4. TITLE AND SUBTITLE</b> Targeting BRCAness in Gastric Cancer					<b>5a. CONTRACT NUMBER</b>	
					<b>5b. GRANT NUMBER</b> W81XWH-16-1-0472	
					<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Dr. Lawrence Fong, MD  E-Mail:Lawrence.Fong@ucsf.edu					<b>5d. PROJECT NUMBER</b>	
					<b>5e. TASK NUMBER</b>	
					<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA. SAN FRANCISCO 1855 FOLSOM ST STE 425 SAN FRANCISCO CA 94103-4249					<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
					<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited						
<b>13. SUPPLEMENTARY NOTES</b>						
<b>14. ABSTRACT</b> In the past year, we have made substantial progress in the project's goals. We have set up a system (described below) to interrogate gastric cancer cells with ATR and PARP inhibitors. This screening platform is now up and running and we are prosecuting preliminary hits. Over the next year, we will validate hits generated here and further the interrogation of clinical samples.						
<b>15. SUBJECT TERMS</b> Gastric cancer, BRCAness, DNA repair, DNA damage, PARP inhibitor, MEK inhibitor.						
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>	
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			USAMRMC	
Unclassified	Unclassified	Unclassified	Unclassified	15	<b>19b. TELEPHONE NUMBER</b> (include area code)	

## 1. Introduction

Inactivating germline and somatic mutations affecting genes involved in DNA damage repair are features of upper gastrointestinal malignancies, but we do not know how common these lesions are. Genes encoding for proteins important for mismatch, base-excision, and homologous recombination (HR) repair are affected in subsets of these tumors. For example, mutations in the HR genes *BRCA1* and *BRCA2* have been found in some gastric cancers. Loss of *BRCA1* protein expression has been found in 21% of gastric cancers and was associated with diffuse-type histology and poor survival. PARP1 (polyADP ribose polymerase 1) is an enzyme essential for base-excision repair, a complementary DNA repair pathway to the HR repair pathway inactivated by mutations in *BRCA1* and *BRCA2*. Inactivation of PARP1 enzymatic activity, and thereby base-excision repair, can produce a synthetic lethality in cells lacking HR function. Clinical activity of single agent PARP inhibitors has been observed in patients with germ-line *BRCA1/2* mutations as well as tumors displaying “BRCAness”, which is characterized by genomic instability and susceptibility to PARP inhibitors in the absence of *BRCA1/2* mutations. Mutations conferring BRCAness have been identified in a number of genes involved in the DNA damage response, including *RAD51C*, *ATM*, *ATR*, *MDC1*, *MRE11A*, *PALB2*, *CHK1/2*, *RAD50*, and components of the Fanconi’s anemia repair pathway but the disease-specific relevance of these mutations is not known. Oncogenic signal transduction pathways, such as PI3K as well as RAF-MEK-ERK pathways may be involved in the regulation of the DNA repair machinery.

The purpose of this research is to elucidate a) whether GI malignancies with mutations in genes conferring BRCAness will be sensitive to PARP inhibition, in particular in combination with inhibitors of oncogenic signal transduction pathways (MEK, PI3K, TGF $\beta$ , WNT, Notch, Hedgehog, JAK-STAT) or with chemotherapy; b) whether mutations conferring BRCAness provoke an immune response that could be enhanced pharmacologically; c) whether there is a DNA signature predictive of PARP inhibitor sensitivity or combinatorial therapies. Addressing these questions will set the stage for development of increasingly efficient treatment strategies for GI cancers involving PARP inhibitors.

## 2. Keywords.

Gastric cancer, BRCAness, DNA repair, DNA damage, PARP inhibitor, MEK inhibitor.

## 3. Accomplishments

### What were the major goals of the project?

1. Obtain clinical samples from PARP inhibitor treated gastric cancers.
2. Apply genomic signatures of “BRCAness” to gastric cancer clinical samples.
3. Identify genes that drive resistance or sensitivity to PARP and ATR inhibition in gastric cancer cells.
4. Validation studies and analysis of archival tissue.

### What was accomplished under these goals?

**Goal 1.** Obtain clinical samples from PARP inhibitor treated gastric cancers.

In the original proposal, we were to perform TCR sequencing on samples derived from Dr. Korn’s Study. Unfortunately, the drug company that Dr. Korn was working with withdrew support for the clinical trial. Dr. Collisson has Dr. Mike Cecchin at Yale, who can provide the needed samples from his clinical trial on which we can now perform TCR sequencing.

## Goal 2. Apply genomic signatures of “BRCAness” to gastric cancer clinical samples.

Previously our preliminary analysis indicated that gastric tumors do not appear to manifest a mutational signature consistent with HRD, at least in the cohort analyzed here. We are making efforts to obtain samples of patients with HR-deficient gastric cancer to assess them for presence of a genomic scar in the coming year.


## Goal 3: Identify genes that drive resistance or sensitivity to PARP and ATR inhibition in gastric cancer cells.

From the last report we generated a list of 57 potential genes whose knockdown associated with ATRi resistance. CRISPRi-mediated knockdown of CDK2 was the strongest inducer of resistance to AZD6738, and promisingly, this hit was previously identified by our lab as an important mediator of ATRi resistance. CDK2 will be one of positive controls for induction of resistance to ATR inhibition. We have selected 7 additional candidate genes for validation, and have included these in the construction of a smaller targeted validation screen. Several additional control sgRNAs are also included in that group, and these are described in **Table 1**.

**Table 1:** Control sgRNAs included on our validation screen

Type	Gene	Purpose
Test	CDK2	sgRNA leads to resistance in screen previously published by our lab
Control	ATR	Target gene
Control	PLK1	Essential gene
Control	<i>ARID1A</i>	Synthetically lethal partner with ATR inhibitor
Control	<i>TP53</i>	ATR inhibition is synthetically lethal in <i>TP53</i> mutant CLL cells
Control	<i>SLFN11</i>	Schlafen-11 inhibits RNA synthesis. Involved in PARPi resistance
Control	<i>CDC25A</i>	<i>CDC25A</i> a major determinant of sensitivity to ATR inhibition

For our validation screen, we will use the complementary gene-editing tool, Cas9 RNPs, in a multi-well high throughput format (**Figure 1**). Three unique crRNAs targeting each gene along with non-targeting controls will be complexed with a tracer RNA and Cas9 protein to form a RNP. Using the Lonza Amaxa 96-well shuttle electroporator, we will electroporate these RNPs into nuclear-tagged AGS cells, which are then seeded into multiple 384 well plates. We will extract genomic DNA from each of these samples too for later PCR, sequencing and knockout analysis. 24 hours later, these cells are treated with DMSO control or AZD6784 (concentrations = SF50, SF25, SF5). We will assess the growth of these cells twice daily for 7 days using the Incucyte Live-Cell Analysis System.



**Figure 1:** Workflow for RNP mini-screen to validate candidate ATRi resistance genes in AGS cells.

## Goal 5. Validation studies and analysis of archival tissue (Janjigian et al Cancer Discovery 2018)

We observed no single gene in DNA repair pathways, such as BRCA1/2, were significantly associated with treatment response when we correlated the genomic findings with treatment response and patient outcomes in the 187 patients with HER2-negative disease treated with first-line fluoropyrimidine/platinum.

## IMPACT

### What opportunities for training and professional development has the project provided?

Reflecting her academic and research achievements, in 2018, Dr. Janjigian was appointed Chief of MSK's Gastrointestinal Oncology Service. This service is one of the largest at MSKCC and Dr. Janjigian's selection as its leader after an international search is a testament to her remarkable accomplishments.

### How were the results disseminated to communities of interest?

National meetings and manuscript published in Cancer Discovery 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9. PMID: 29122777

A second manuscript outlining the rapid autopsy data is in re-submitted for second review to Cancer Discovery

### What do you plan to do during the next reporting period to accomplish the goals?

We will keep expanding the cohort of PDX to better reflect our diverse patient population.

**What was the impact on technology transfer?**

Nothing to report

**What was the impact on society beyond science and technology?**

Nothing to report

**CHANGES/PROBLEMS**

**Changes in approach and reasons for change**

None

**Actual or anticipated problems or delays and actions or plans to resolve them**

Nothing to report

**Changes that had a significant impact on expenditures**

Nothing to report

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to report

**PRODUCTS**

**• Publications, conference papers, and presentations**

published in Cancer Discovery 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9. PMID: 29122777

A second manuscript outlining the rapid autopsy data is in re-submitted for second review to Cancer Discovery

**Books or other non-periodical, one-time publications.**

Nothing to report

**Other publications, conference papers, and presentations**

Nothing to report

**• Website(s) or other Internet site(s)**

Nothing to report

**• Technologies or techniques**

Improved efficacy of tumor implantation to immune deficient mice

1. Dissect human tumor to 100mm<sup>3</sup> pieces
2. With blunt edge of scissors, scrape off soft/whitish necrotic tissue
3. Cut the fragment to 20-30mm<sup>3</sup> pieces by removing non-viable tissue
4. Implant these 20-30mm<sup>3</sup> pieces in bilateral flank of immune deficient mice as described anywhere

- **Inventions, patent applications, and/or licenses**

Nothing to report

- **Other Products**

Nothing to report